STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by STAT News; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories
Why it mattersMissouri attorney general warned Eli Lilly to discontinue requiring hospitals to provide claims data to receive discounted medicines under 340B program
By Chella·27m ago
Why it mattersData add to expectations that the drug will be one of Lilly’s greatest growth drivers.
By Chella·3h ago
Why it mattersAfter years of steep increases, especially amid the pandemic, U.S. overdose deaths decreased 27% in 2024, and preliminary data from 2025 show another meaningful drop.
By Chella·2h ago
Why it mattersA STAT investigation found that Epic selectively withholds access to patient data, disadvantaging rival software developers and stymying innovation.
By Chella·5h ago